You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. High-density optical tomography of cerebral blood flow and metabolism in small animals

    SBC: BIOPTICS TECHNOLOGY LLC            Topic: 105

    ABSTRACT Many clinical situations, including stroke, expose the brain to insufficient cerebral blood flow (CBF) that cannot maintain normal cerebral metabolic rate of oxygen consumption (CMRO2) requirements, thereby leading to cerebral ischemic/hypoxic stresses and neurological disorders. Effective interventions are dependent on the findings of CBF/CMRO2 improvement and eventually neural recovery. ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  2. Bioethical Considerations for Building, Evaluating, and Implementing Artificial Intelligence in Perinatal Mood and Anxiety Disorders

    SBC: Iris OB Health Inc.            Topic: 104

    PROJECT SUMMARY Postpartum depression (PPD) is a common, yet treatable illness if detected early, but it can also have deleterious effects to the mother and child if left untreated. Routine screening for PPD is considered best practice but does not consistently occur due to time and resource constraints. As a result, therapeutic interventions are initiated late and many PPD cases go undetected alt ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  3. A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.

    SBC: TEZCAT Laboratories LLC            Topic: 102

    Project Summary: TEZCAT Laboratories LLC is an early-stage, Austin-based biotechnology company developing novel biologics with a unique mechanism of action to treat the most recalcitrant cancers, such as mutant KRas pancreatic cancer. As an alternative to targeting mutant KRas itself, much attention has been paid to targeting cellular events that are a result of mutant KRas. New efforts are underw ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Novel Therapeutic Molecules for Treatment of Squamous Head and Neck Cancers

    SBC: Mekanistic Therapeutics, LLC            Topic: 102

    Mekanistic Therapeutics seeks to design, discover, and develop anti-cancer agents that selectively inhibit multiple oncogenic pathways. Among Mekanistic’s portfolio are dual and highly selective inhibitors of EGFR and PI3 kinase, which were rationally designed to only target these two critical oncogenes. The PI3 kinase (PI3K)/AKT/mTOR pathway plays a central role in driving tumor cell survival a ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a biomarker panel for screening and early detection of gynecological cancers

    SBC: MDDx, Inc.            Topic: 102

    PROJECT SUMMARY It is estimated that more than 80,000 women will be diagnosed with ovarian (OvCA) and endometrial (EndoCA) cancers this year in the U.S. and this will result in the death of 26,000 women. There are no screening tests for either of these two female-specific cancers which also disproportionally affect ethnically distinct populations. For both cancers, detection of early stage, locali ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Controlled-release Microbeads to Replace Growth Factors in Fetal Bovine Serum

    SBC: STEM CULTURES LLC            Topic: 400

    Project Summary / Abstract: Fetal bovine serum (FBS) contains a variety growth factors (GFs) and GF-stabilizing agents that have a potent influence on cell behavior. Lot-to-lot variability of FBS, however, results in fluctuation of initial GF levels. These fluctuations are further complicated by time-dependent decay at rates unique to each GF, resulting in changing GF ratios over time. These three ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Modular Adaptive Virtual Reality Intervention for Clinical Substance use disorder (MAVRICS)

    SBC: INNATEVR LLC            Topic: NIDA

    PROJECT SUMMARY/ABSTRACT Opioid Use Disorder (OUD) is a chronic, recurring condition that if left untreated, poses a significant and ongoing public health threat. OUD is associated with significant impairments in physical and psychological health including increased mortality and high utilization of emergency medical care as well as increased risk of Hepatitis C and HIV infection and Neonatal Abst ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Transient Gene Therapy as Broad Spectrum Antiviral

    SBC: LAB11 THERAPEUTICS INC.            Topic: NIAID

    Project Summary Currently there are very few antiviral drugs, and no broad-spectrum antiviral drugs. For example, Influenza A virus (IAV) causes 12,000-56,000 deaths and 150,000-750,000 hospitalizations annually in the US alone, despite the availability of vaccines and five FDA-approved drugs 1, 2. Resistance to two of the five existing drugs has already emerged 13. Second, SARS-CoV-2 a virus whic ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Gene therapy to treat glaucoma by reducing intraocular pressure

    SBC: Advanced Vision Technologies, Inc.            Topic: NEI

    Abstract In the U.S., glaucoma is the leading cause of irreversible blindness, with ~120,000 of the over 2.7 million people with glaucoma being blind. Notably, the prevalence of glaucoma is expected to climb significantly as the U.S. population ages, with annual medical costs predicted to reach over $17 billion by 2050. Open angle glaucoma (OAG) is a group of slowly progressive, potentially blindi ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. New Treatments for Glaucoma

    SBC: GRANNUS THERAPEUTICS, INC.            Topic: NEI

    Abstract Aggregation of mutated myocilin (MYOC), a protein found in the endoplasmic reticulum (ER) of trabecular meshwork (TM) cells, disrupts the outflow of aqueous humor from the eye, causing increase in intraocular pressure (IOP), progressive retinal ganglion cell (RGC) death, and degeneration of the optic nerve, leading to primary open-angle glaucoma (POAG), characterized by irreversible visio ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government